ClinicalTrials.gg
CompletedNCT05937737Updated Jul 11, 2023

Serum FGF21 Levels and Dietary Total Antioxidant Capacity in Type 2 Diabetes

An interventional study of Type 2 Diabetes Diet Modification in Type 2 Diabetes, sponsored by Hacettepe University. Completed at 2 sites in Turkey (Türkiye). Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-11.

Sponsored by Hacettepe University · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Apr 2020, registered Jun 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
19 Years to 64 Years
Sex
All
01

Study summary

This study aimed to evaluate the phytochemicals and total antioxidant capacity in the diets of individuals with type 2 diabetes and assess their relationship with glycemic parameters, as well as certain biochemical parameters and Fibroblast growth factor 21 (FGF21), which is an inflammatory marker. The study was conducted on a total of 80 individuals, including 40 patients with overweight or obesity (Body Mass Index (BMI) > 25 kg/m²) with type 2 diabetes aged between 18 and 64, and 40 healthy controls (BMI between 18.5-35 kg/m²). The individuals were followed for 12 weeks with an appropriate diet. Biochemical parameters, anthropometric measurements, and dietary intake records were monitored at specific intervals throughout the study. The phytochemical index and total antioxidant capacity of the individuals' diets were measured, and FGF21 was examined in the serum.

Read the detailed description

Individuals were divided into two groups: type 2 diabetes and control. Individuals with type 2 diabetes were followed for 12 weeks with an appropriate diet specific to their condition, and necessary measurements were taken at the beginning, 4th week, and 12th week. No dietary intervention was made for the control group, and necessary measurements were taken at the beginning and 12th week. At the control points, biochemical parameters, serum samples, anthropometric measurements (body composition, weight, height, waist circumference, hip circumference), 24-hour dietary intake record, and 24-hour physical activity record were evaluated. In the experimental group, dietary intake was recorded at the beginning (week 0), 4th week, and 12th week. The dietary intake of the control group was examined at week 0 and week 12.

The "Phytochemical Index" method was used to calculate the total phytochemical intake from the diet. The total antioxidant capacity of the diet was calculated using data obtained from dietary intake records based on Ferric Reducing Ability of Plasma (FRAP), Oxygen Radical Absorbance Capacity (ORAC), Trolox Equivalent Antioxidant Capacity (TEAC), and Total Reactive Antioxidant Potential (TRAP) methods. Additionally, physical activity was determined using a recording method. Body compositions at all three control points will be determined using the bioelectrical impedance method, and waist and hip circumference measurements were taken using a non-stretchable tape measure. Routine biochemical parameters for the type 2 diabetic group (fasting blood glucose, serum lipids, HbA1c) were obtained from the records. Serum samples collected after a 10-12 hour fasting period at the beginning and 12th week were analyzed for Fibroblast growth factor 21 (FGF21) using suitable kits.

02

Conditions studied

  • Type 2 Diabetes

Keywords

  • FGF-21
  • type 2 diabetes
  • antioxidant capacity
  • phytochemical index
03

In context

Diabetes Mellitus, Type 2

9,589 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,332 are open to participants now.

This study's enrollment of 76 is close to the median of 81 across 7,713 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Hacettepe University is the lead sponsor of 1,001 studies on the registry; 215 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For intervention group: type 2 diabetes diagnosis
  • For control group: healthy individuals
  • Aged between 19 and 64
  • With a body mass index over 25 kg/m²

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Type 1 diabetes
  • Cancer
  • Chronic kidney disease
  • Chronic liver disease
  • Other chronic inflammatory diseases
  • Individuals with HbA1c levels above 9%
  • Individuals using short or medium-acting or mixed (medium+short) insulin
  • Individuals with any condition that hinders physical activity
  • Individuals following any weight loss diet
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Type 2 Diabetes

    Individuals with type 2 diabetes were followed for 12 weeks with an appropriate diet specific to their type 2 diabetes condition, and necessary measurements were taken at the beginning, 4th week, and 12th week.

    Behavioral: Type 2 Diabetes Diet Modification

  • No intervention
    Healthy Controls

    No dietary intervention was made for the control group, and necessary measurements were taken at the beginning and 12th week.

Interventions

  • BehavioralType 2 Diabetes Diet Modification

    A 12-week dietary intervention model was prescribed to the patients in accordance with their needs.

06

What researchers measure

Primary outcomes

  1. Fibroblast growth factor 21 (FGF21)

    FGF21 levels in serum

    Time frame: 12 weeks

  2. Body weight

    Body weight measurements

    Time frame: 12 weeks

  3. Body fat percentage

    Body fat percentage measured with bioelectrical impedance analysis

    Time frame: 12 weeks

  4. Phytochemical index

    Dietary phytochemical index

    Time frame: 12 week

  5. Ferric Reducing Ability of Plasma (FRAP)

    Dietary antioxidant capacity measured with FRAP method

    Time frame: 12 weeks

  6. Oxygen Radical Absorbance Capacity (ORAC)

    Dietary antioxidant capacity measured with ORAC method

    Time frame: 12 weeks

  7. Trolox Equivalent Antioxidant Capacity (TEAC)

    Dietary antioxidant capacity measured with TEAC method

    Time frame: 12 weeks

  8. Total Reactive Antioxidant Potential (TRAP)

    Dietary antioxidant capacity measured with TRAP method

    Time frame: 12 weeks

07

Study locations

2 sites
  • Hacettepe University Internal Medicine Department
    Ankara, 06100, Turkey (Türkiye)
  • Hacettepe University Nutrition and Dietetics Department
    Ankara, 06100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05937737
Responsible party
Zeynep Goktas (Principal Investigator, Hacettepe University) — Principal investigator
First posted
Jul 10, 2023
Start date
Apr 20, 2020
Primary completion
Dec 30, 2021
Completion
Apr 15, 2022
Last update
Jul 11, 2023

Study contacts

Zeynep Goktas, PhD
principal investigator · Hacettepe University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion